PMID- 35445052
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231102
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 9
DP  - 2022
TI  - Cardiovascular Protective Effects of Oral Hypoxia Inducible Factor Prolyl 
      Hydroxylase Inhibitor Roxadustat in the Treatment of Type 4 Cardiorenal-Anemia 
      Syndrome: Protocol of a Randomized Controlled Trial.
PG  - 783387
LID - 10.3389/fmed.2022.783387 [doi]
LID - 783387
AB  - BACKGROUND: Patients with chronic kidney disease (CKD) are at high risk of 
      developing heart failure and anemia, which is defined as type 4 
      cardiorenal-anemia syndrome (CRAS). CRAS aggravates the deterioration of both 
      kidney and heart function, ultimately resulting in a high mortality. This study 
      aims to examine the efficacy and safety of roxadustat in the treatment of type 4 
      CRAS. METHODS AND DESIGN: This study is designed as a randomized, open-label, 
      controlled trial. A total of 68 patients diagnosed with type 4 CRAS will be 
      randomly divided into roxadustat group and erythropoietin with a 1:1 ratio. 
      Participants in the roxadustat group will receive roxadustat with an initial dose 
      of 70 or 100 mg three times a week, and participants in the erythropoietin group 
      will receive subcutaneous injection of erythropoietin for 24 weeks, to maintain a 
      hemoglobin ranging from 100 to 120 g per liter. The primary outcome is the change 
      in heart function, including brain natriuretic peptide (BNP), 6-min walk test 
      (6-WT), and left ventricular ejection fraction (LVEF). Secondary outcomes to be 
      assessed include death, cardiovascular events, hospitalization regarding heart 
      failure, Minnesota Heart Failure Quality of life scale (MLHFQ) score, New York 
      Heart Association (NYHA) cardiac function grade, echocardiographic parameters 
      including left ventricular diastolic diameter and volume (LVDD and LVDV) and 
      ventricular mass (LVM), anemia related parameters, inflammatory parameters, and 
      safety assessments. CONCLUSION: The findings of this study will provide potential 
      evidence for roxadustat in CRAS management. TRIAL REGISTRATION: Chinese Clinical 
      Trial Registry, ID: ChiCTR2100050031. Registered on 16 August 2021.
CI  - Copyright (c) 2022 Wen, Xu, Tian, Jiang, Jiang and Li.
FAU - Wen, Yumin
AU  - Wen Y
AD  - Department of Nephrology, Beijing Hepingli Hospital, Beijing, China.
FAU - Xu, Yang
AU  - Xu Y
AD  - Department of Nephrology, Beijing Hepingli Hospital, Beijing, China.
FAU - Tian, Hui
AU  - Tian H
AD  - Department of Nephrology, Beijing Hepingli Hospital, Beijing, China.
FAU - Jiang, Sizhu
AU  - Jiang S
AD  - Department of Nephrology, Beijing Hepingli Hospital, Beijing, China.
FAU - Jiang, Guofang
AU  - Jiang G
AD  - Department of Nephrology, Beijing Hepingli Hospital, Beijing, China.
FAU - Li, Puqing
AU  - Li P
AD  - Department of Nephrology, Beijing Hepingli Hospital, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20220404
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC9013811
OTO - NOTNLM
OT  - anemia
OT  - cardiorenal-anemia syndrome
OT  - chronic kidney disease
OT  - heart failure
OT  - roxadustat
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/04/22 06:00
MHDA- 2022/04/22 06:01
PMCR- 2022/04/04
CRDT- 2022/04/21 05:45
PHST- 2021/09/26 00:00 [received]
PHST- 2022/03/07 00:00 [accepted]
PHST- 2022/04/21 05:45 [entrez]
PHST- 2022/04/22 06:00 [pubmed]
PHST- 2022/04/22 06:01 [medline]
PHST- 2022/04/04 00:00 [pmc-release]
AID - 10.3389/fmed.2022.783387 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2022 Apr 4;9:783387. doi: 10.3389/fmed.2022.783387. 
      eCollection 2022.